Will Onconova climbs up to $4?

$Onconova Therapeutics, Inc.(ONTX)$ The microcap pharmaceutical company, Onconova Therapeutics (NASDAQ:ONTX) has added ~26.1% in the pre-market after Guggenheim analyst Etzer Darout initiated its coverage with a buy rating and a Street high price target of $4.00 per share to imply ~545.2% upside to the last close.

The company’s lead product candidate ON 123300 is a multi-kinase inhibitor that targets CDK (Cyclin-dependent kinase) 4 and 6 which are believed to be overexpressed in a range of cancers, including HR+ HER 2- metastatic breast cancer.

The company has “differentiated” CDK, eyeing a multi-billion-dollar category, the analyst argues calling ON 123300 Onconova’s main value driver with a potential market opportunity of ~$8B in the global CDK4/6 market.

Darout also points to rigosertib citing its upside optionality in RAS+ solid tumors. Rigosertib is currently undergoing an investigator-initiated Phase 1/2 study program, in combination with nivolumab targeting patients with KRAS+ non-small cell lung cancer.

Do you think Onconova will climb up to $4? What's your take on this?

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

BLESSED55
2021-05-19
BLESSED55
I your prediction is correct :)

Leave a comment

1

10

{"i18n":{"language":"en_US"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":194725856,"tweetId":"194725856","gmtCreate":1621403167371,"gmtModify":1704357068022,"author":{"id":3579612413176972,"idStr":"3579612413176972","authorId":3579612413176972,"authorIdStr":"3579612413176972","name":"Yonny","avatar":"https://static.tigerbbs.com/7a670199f288b462a1f2c0da783cc671","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":9,"crmLevelSwitch":1,"individualDisplayBadges":[],"fanSize":4893,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"Will Onconova climbs up to $4?","extraTitle":"","html":"<html><head></head><body><p><a href=\"https://laohu8.com/S/ONTX\">$Onconova Therapeutics, Inc.(ONTX)$</a> The microcap pharmaceutical company, Onconova Therapeutics (NASDAQ:ONTX) has added ~26.1% in the pre-market after Guggenheim analyst Etzer Darout initiated its coverage with a buy rating and a Street high price target of $4.00 per share to imply ~545.2% upside to the last close.&nbsp;</p> <p>The company’s lead product candidate ON 123300 is a multi-kinase inhibitor that targets CDK (Cyclin-dependent kinase) 4 and 6 which are believed to be overexpressed in a range of cancers, including HR+ HER 2- metastatic breast cancer.</p> <p>The company has “differentiated” CDK, eyeing a multi-billion-dollar category, the analyst argues calling ON 123300 Onconova’s main value driver with a potential market opportunity of ~$8B in the global CDK4/6 market.</p> <p>Darout also points to rigosertib citing its upside optionality in RAS+ solid tumors. Rigosertib is currently undergoing an investigator-initiated Phase 1/2 study program, in combination with nivolumab targeting patients with KRAS+ non-small cell lung cancer.</p> <p>Do&nbsp;you&nbsp;think&nbsp;Onconova will&nbsp;climb up to $4?&nbsp;What's&nbsp;your&nbsp;take&nbsp;on&nbsp;this?&nbsp;</p></body></html>","htmlText":"<html><head></head><body><p><a href=\"https://laohu8.com/S/ONTX\">$Onconova Therapeutics, Inc.(ONTX)$</a> The microcap pharmaceutical company, Onconova Therapeutics (NASDAQ:ONTX) has added ~26.1% in the pre-market after Guggenheim analyst Etzer Darout initiated its coverage with a buy rating and a Street high price target of $4.00 per share to imply ~545.2% upside to the last close.&nbsp;</p> <p>The company’s lead product candidate ON 123300 is a multi-kinase inhibitor that targets CDK (Cyclin-dependent kinase) 4 and 6 which are believed to be overexpressed in a range of cancers, including HR+ HER 2- metastatic breast cancer.</p> <p>The company has “differentiated” CDK, eyeing a multi-billion-dollar category, the analyst argues calling ON 123300 Onconova’s main value driver with a potential market opportunity of ~$8B in the global CDK4/6 market.</p> <p>Darout also points to rigosertib citing its upside optionality in RAS+ solid tumors. Rigosertib is currently undergoing an investigator-initiated Phase 1/2 study program, in combination with nivolumab targeting patients with KRAS+ non-small cell lung cancer.</p> <p>Do&nbsp;you&nbsp;think&nbsp;Onconova will&nbsp;climb up to $4?&nbsp;What's&nbsp;your&nbsp;take&nbsp;on&nbsp;this?&nbsp;</p></body></html>","text":"$Onconova Therapeutics, Inc.(ONTX)$ The microcap pharmaceutical company, Onconova Therapeutics (NASDAQ:ONTX) has added ~26.1% in the pre-market after Guggenheim analyst Etzer Darout initiated its coverage with a buy rating and a Street high price target of $4.00 per share to imply ~545.2% upside to the last close. The company’s lead product candidate ON 123300 is a multi-kinase inhibitor that targets CDK (Cyclin-dependent kinase) 4 and 6 which are believed to be overexpressed in a range of cancers, including HR+ HER 2- metastatic breast cancer. The company has “differentiated” CDK, eyeing a multi-billion-dollar category, the analyst argues calling ON 123300 Onconova’s main value driver with a potential market opportunity of ~$8B in the global CDK4/6 market. Darout also points to rigosertib citing its upside optionality in RAS+ solid tumors. Rigosertib is currently undergoing an investigator-initiated Phase 1/2 study program, in combination with nivolumab targeting patients with KRAS+ non-small cell lung cancer. Do you think Onconova will climb up to $4? What's your take on this?","highlighted":1,"essential":1,"paper":2,"likeSize":10,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/194725856","repostId":0,"isVote":1,"tweetType":1,"viewCount":5392,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["ONTX"],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":933,"xxTargetLangEnum":"ORIG"},"commentList":[{"id":4378977,"commentId":"4378977","gmtCreate":1621426103498,"gmtModify":1680789702957,"authorId":3575026933942551,"author":{"id":3575026933942551,"idStr":"3575026933942551","authorId":3575026933942551,"name":"BLESSED55","avatar":"https://static.tigerbbs.com/e160ffde9e329fe5c754d7e31e81f438","vip":1,"crmLevel":4,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":194725856,"objectIdStr":"194725856","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"I your prediction is correct :)","text":"I your prediction is correct :)","html":"I your prediction is correct :)","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0}],"isCommentEnd":false,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/194725856"}